跳至主要内容
临床试验/ACTRN12615000203550
ACTRN12615000203550招募中2 期

A phase II randomised, controlled pilot study to evaluate the safety and feasibility of renal denervation in heart failure patients on maximal medical treatment

Dr Suku Thambar0 个研究点目标入组 20 人开始时间: 2015年3月3日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1. Able to comprehend requirements and provide consent.
  • 2. Males or females greater than or equal to 18years.
  • 3. Established congestive heart failure with NYHA Class II-III
  • 4. Left Ventricular Ejection Fraction (LVEF) less than or equal to 35% on echocardiography.
  • 5. Adequate renal function with estimated GFR greater than or equal to 30 mL/min.
  • 6. Optimal stable medical therapy for heart failure for at
  • least 3 months prior to study entry as per ACCF/AHA
  • guidelines.

排除标准

  • 1. Renal artery abnormalities (i.e. too small, presence of significant stenosis, prior angioplasty procedure, multiple main renal arteries).
  • 2. Single functioning kidney.
  • 3. End Stage Renal Disease requiring haemo-dialysis or
  • renal transplant.
  • 4. Unstable vascular syndromes, such as myocardial
  • infarction, unstable angina pectoris or cerebro-vascular
  • accident, within 3 months.
  • 5. Systolic blood pressure less than 100mmHg.
  • 6. Haemodynamically significant valvular heart disease.
  • 7. Pregnant, nursing or planning on becoming pregnant
  • during the course of the study.
  • 8. Enrolled in, or intend to participate in, another
  • investigational drug or device trial.
  • 9. Any concurrent disease or condition that, in the opinion
  • of the investigator, would make the subject unsuitable
  • for participation in the study.

研究者

发起方
Dr Suku Thambar

相似试验